News
--Hoth Therapeutics, Inc., a leading biopharmaceutical company focused on patient-centric solutions, today shared encouraging interim safety and efficacy results from its Phase 2 a clinical trial ...
Hoth Therapeutics' HT-001 Achieves 100% Response Rate in at least one endpoint in Phase 2a Trial in PK Patients for EGFR Inhibitor-Related Skin Toxicities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback